Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-165"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101122.17.1-165"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Madam President, how often do we wonder about the side-effects of medicines we are taking? How often do we wish for more information on products and illnesses? This report deals with these questions and the need the public has for information.
The change of focus from the original Council proposals was important, as was the emphasis on the patient’s right to access information as opposed to the possibility of pharmaceutical companies providing information. This was achieved by a ban on direct consumer advertising for prescription-only medicines.
In addition, an important issue was the recognition of the national competent authority and healthcare professionals as the main source of information. Again, this was achieved.
The Information to Patients Directive sends a strong message on the rights of patients.
I congratulate the rapporteur on tackling a difficult dossier and producing a comprehensive directive which, I hope, we will all support unitedly."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples